Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereotactic Tenecteplase Thrombolysis for Supratentorial Intracerebral Hemorrhage
ChiCTR2500105953Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tenecteplase in intracerebral hemorrhage (ICH) (2 arms), sponsored by Tongji Hospital. Primary endpoints: All-cause mortality within 30 days post-randomization and Proportion of subjects with mRS 0–3 at 180 days. Started Jul 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR2500105953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105953.